Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Climacteric ; 27(1): 41-46, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38174425

ABSTRACT

We summarize convincing evidence that future cardiovascular disease (CVD) risk increases one-fold to four-fold for women with a history of pregnancy complicated by hypertensive disorders, gestational diabetes, fetal growth restriction, placental abruption and preterm birth. A concomitant occurrence of two or more complications in the same pregnancy further potentiates the risk. These women should be informed of their future CVD risks during the postpartum check-up taking place after delivery, and also, if needed, treated, for example, for persisting high blood pressure. In these women with high blood pressure, check-up should take place within 7-10 days, and if severe hypertension, within 72 h. Women without diagnostic signs and symptoms should be examined for the first time 1-2 years postpartum and then at intervals of 2-3 years for a complete CVD risk profile including clinical and laboratory assessments. Women should be informed for future CVD risks and their effective prevention with healthy lifestyle factors. Combined oral contraceptives should be avoided or used with caution. If laboratory or other clinical findings indicate, then vigorous treatments consisting of non-medical and medical (antihypertensives, statins, antidiabetic and anti-obesity therapies) interventions should be initiated early with liberal indications and with ambitious therapeutic goals. Low-dose aspirin and menopausal hormone therapy should be used in selected cases. Active control and treatment policies of these women with pregnancy-related risks will likely result in decreases of CVD occurrence in later life.


Subject(s)
Cardiovascular Diseases , Hypertension , Premature Birth , Pregnancy , Female , Infant, Newborn , Humans , Cardiovascular Diseases/etiology , Cardiovascular Diseases/prevention & control , Cardiovascular Diseases/epidemiology , Premature Birth/prevention & control , Placenta , Risk Factors
2.
Climacteric ; 26(6): 571-576, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37477982

ABSTRACT

OBJECTIVE: We compared the trends of hormone therapy (HT) use among women with and without a history of pre-eclampsia. METHODS: This national cohort study consisted of women with a pre-eclamptic pregnancy (n = 31,688) or a normotensive pregnancy (n = 91,726) (controls) during 1969-1993. The data on their use of HT during 1994-2019 were traced from the National Medicine Reimbursement Register. RESULTS: Both women with a history of pre-eclampsia and controls initiated HT at a mean age of 49.9 years. Cumulative HT™ use during the total follow-up did not differ between the groups (31.1% vs. 30.6%, p = 0.066). However, HT use in previously pre-eclamptic women was less common in 1994-2006 (20.2% vs. 22.4%, p < 0.001) and more common in 2007-2019 (22.1% vs. 21.1%, p < 0.001) than in controls. This trend was also seen in the annual changes of HT starters. Women with a history of pre-eclampsia used HT for a shorter time (6.3 vs. 7.1 years, p < 0.001). CONCLUSIONS: In contrast to controls, HT use in previously pre-eclamptic women increased during the last half of the follow-up. This may reflect the changes in the international recommendations, the increased awareness of pre-eclampsia-related cardiovascular risk later in life and the aim to diminish this risk with HT.


Subject(s)
Pre-Eclampsia , Pregnancy , Female , Humans , Middle Aged , Pre-Eclampsia/epidemiology , Cohort Studies , Estrogen Replacement Therapy/adverse effects , Finland/epidemiology , Blood Pressure
3.
Climacteric ; 22(3): 263-269, 2019 06.
Article in English | MEDLINE | ID: mdl-30773062

ABSTRACT

Stress urinary incontinence (SUI) affects millions of women worldwide. Pelvic floor muscle training is the first-line treatment for SUI, and if this fails, midurethral sling surgery has become the gold-standard treatment. More recently, complications from midurethral mesh slings, particularly chronic pain and dyspareunia, have become a major concern. Although traditional SUI treatments, such as colposuspension and fascia slings, are used, the future of SUI treatment likely will rely on less invasive alternatives. Modern bulking agents could have the potential to become a first-line treatment for SUI, but further long-term studies are needed. Patients should be involved in decision-making prior to any surgery to ensure that they are aware of the risks and also any reasonable treatment alternatives. Furthermore, the effectiveness of a procedure should be balanced with its invasiveness and possible risks to provide women individually with the best possible treatment option.


Subject(s)
Suburethral Slings , Urinary Incontinence, Stress/surgery , Female , Humans , Urologic Surgical Procedures
4.
Climacteric ; 20(1): 5-10, 2017 Feb.
Article in English | MEDLINE | ID: mdl-28042727

ABSTRACT

Coronary artery disease (CAD) is still the most common killer of western women. Coronary arteries, expressing estrogen receptors, are a target for estrogen action. Prior to the Women's Health Initiative (WHI) study, postmenopausal hormone therapy (HT) was widely advocated for primary prevention of CAD, but such use was criticized after the WHI publication. However, new data accumulated in the USA and in Europe indicate that the use of estradiol-based HT regimens does not endanger the heart, but rather, it significantly reduces the incidence of CAD events and mortality. This effect may be related to the presence of hot flushes before HT initiation, because they may indicate a greater responsiveness of the cardiovascular system to HT. To get maximal cardioprotective efficacy of HT, a woman should initiate HT as soon as symptoms occur, and preferably within the first 10 postmenopausal years. Recent guidelines for optimal use of HT recommend pauses of HT at 1-2-year intervals to see whether hot flushes and other symptoms still persist. However, new data question the safety of this policy, because acute withdrawals of estradiol from the circulation may predispose to potentially fatal CAD events. All these data support modernized guidelines for optimal HT use.


Subject(s)
Cardiotonic Agents/administration & dosage , Coronary Artery Disease/prevention & control , Estrogen Replacement Therapy/methods , Estrogens/administration & dosage , Postmenopause/drug effects , Drug Administration Schedule , Estradiol/administration & dosage , Female , Hot Flashes/drug therapy , Humans , Middle Aged
5.
Climacteric ; 15(2): 153-6, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22017369

ABSTRACT

AIM: To study a possible association between the potent vasodilatory nitric oxide and postmenopausal hot flushes. METHODS: We compared the release of nitric oxide in 150 recently menopausal women reporting no (n = 23), mild (n = 34), moderate (n = 30), or severe (n = 63) hot flushes. Plasma samples, collected after a 48-h arginine-poor diet, were assessed for the metabolites of nitric oxide (NOx), using the Griess reaction. RESULTS: Levels of NOx showed no association with the severity of hot flushes. Furthermore, no relationships with individual hot flushes and serum levels of estradiol or high-sensitivity C-reactive protein were detected. CONCLUSIONS: These preliminary data indicate that nitric oxide appears not to be a factor in hot flushes and might not be related to their etiology. Since a fasting plasma NOx measurement may not reflect what happens at the time of the hot flush episode, in future studies there should be an attempt to assess nitric oxide release during a concomitant hot flush.


Subject(s)
Hot Flashes/blood , Nitrates/blood , Nitrites/blood , Postmenopause/blood , C-Reactive Protein/metabolism , Estradiol/blood , Female , Humans , Middle Aged , Nitric Oxide/blood , Severity of Illness Index , Statistics, Nonparametric
6.
Climacteric ; 13(5): 457-66, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20443719

ABSTRACT

INTRODUCTION: Menopausal hot flushes may affect the responses of various vascular risk factors to hormone therapy (HT). We compared the responses of biochemical markers for cardiovascular diseases to HT in recently postmenopausal women with tolerable or intolerable hot flushes. METHODS: Healthy, non-smoking freshly postmenopausal women (n = 150) with no previous HT use were studied. Seventy-two women reported intolerable hot flushes (> or =7 moderate/severe episodes/day) and 78 women tolerable hot flushes (< or =3 mild episodes/day). The participants were treated in randomized order with either transdermal estradiol gel (1 mg), oral estradiol valerate (2 mg) with or without medroxyprogesterone acetate (5 mg), or placebo for 6 months. Treatment-induced changes in lipids, lipoproteins, apolipoproteins, sex hormone binding globulin (SHBG) and high-sensitivity C-reactive protein were compared. The trial is registered in the US National Institutes of Health Clinical Research Registry (no. NCT00668603). RESULTS: Pretreatment hot flush status was not related to the responses of these markers to different forms of HT. However, when all active regimens were evaluated together as a post-hoc analysis, 7/10 markers showed a tendency toward greater beneficial changes in women with intolerable hot flushes. Furthermore, in women with intolerable hot flushes and with HT use, the increases in SHBG (Spearman's rho = - 0.570, p < 0.001) were related to the reductions in hot flushes during the use of HT. CONCLUSIONS: Hot flushes appear to be no significant determinant for the responses of vascular markers to HT use.


Subject(s)
Cardiovascular Diseases/blood , Estrogen Replacement Therapy/methods , Hot Flashes/drug therapy , Postmenopause/blood , Administration, Cutaneous , Administration, Oral , Apolipoprotein A-I/blood , Apolipoproteins B/blood , Biomarkers/blood , C-Reactive Protein/analysis , Cardiovascular Diseases/diagnosis , Estradiol/administration & dosage , Estrogens/administration & dosage , Female , Hot Flashes/blood , Humans , Medroxyprogesterone Acetate/administration & dosage , Middle Aged , Postmenopause/drug effects , Sex Hormone-Binding Globulin/analysis
7.
Climacteric ; 12 Suppl 1: 58-61, 2009.
Article in English | MEDLINE | ID: mdl-19811243

ABSTRACT

The gynecologist is often the only physician a woman consults on a regular basis and therefore gynecologists play a crucial role in the primary prevention of cardiovascular disease. Cardiovascular risk factors in women entering the menopausal transition are poorly managed, partly due to the fact that primary-care physicians, gynecologists and cardiovascular physicians often fail to identify cardiovascular risk factors and also undertreat women at increased cardiovascular risk. Furthermore, most women are not well informed about their cardiovascular risk profile. Gynecologists and cardiologists should work together as a team in identifying and managing cardiovascular risk factors. European cardiologists and gynecologists have written a Consensus statement and a short guide to help menopause physicians to assess and manage the cardiovascular risk in women.


Subject(s)
Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/prevention & control , Gynecology , Physician's Role , Postmenopause , Cardiovascular Diseases/epidemiology , Estrogen Replacement Therapy , Female , Humans , Postmenopause/physiology , Primary Prevention , Risk Assessment
8.
Climacteric ; 11(5): 409-15, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18781486

ABSTRACT

OBJECTIVES: Tibolone is often taken concurrently with soy. Tibolone, soy and equol-producing capacity each affect vascular health, whereas their concomitant effects are unknown. We studied the effects of soy on sex steroids and vascular inflammation markers in long-term tibolone users. METHODS: Postmenopausal women (n = 110) on tibolone were screened with a soy challenge to find 20 equol producers and 20 non-producers. All women were treated for 8 weeks in a cross-over trial with soy (52 g of soy protein containing 112 mg of isoflavones) or placebo. Serum estrone, 17beta-estradiol, testosterone, androstenedione, dehydroepiandrosterone sulfate (DHEAS), sex hormone binding globulin (SHBG), C-reactive protein (CRP), vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and platelet-selectin (P-selectin) were assessed. RESULTS: Soy decreased (7.1%) the estrone level, significantly (12.5%) only in equol producers (from 80.2 +/- 10.8 to 70.3 +/- 7.0 pmol/l; p = 0.04). Testosterone was reduced (15.5%; from 586 +/- 62.6 to 495 +/- 50.1 pmol/l, p = 0.02) during soy treatment, and more markedly in equol producers than non-producers (22.1% vs. 10.0%). No changes appeared in SHBG, CRP or ICAM-1, but VCAM-1 increased (9.2%) and P-selectin decreased (10.3%) during soy treatment. CONCLUSIONS: Soy modified the concentrations of estrone, testosterone and some endothelial markers. Equol production enforced these effects. Soy supplementation may be clinically significant in tibolone users.


Subject(s)
Estrogen Receptor Modulators/therapeutic use , Isoflavones/metabolism , Norpregnenes/therapeutic use , Postmenopause , Soybean Proteins/administration & dosage , C-Reactive Protein/analysis , Cross-Over Studies , Equol , Estrone/blood , Female , Humans , Intercellular Adhesion Molecule-1/blood , Middle Aged , P-Selectin/blood , Sex Hormone-Binding Globulin/analysis , Testosterone/blood , Vascular Cell Adhesion Molecule-1/blood
9.
Climacteric ; 10(6): 471-9, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18049940

ABSTRACT

OBJECTIVES: Equol, a gut bacterial metabolite of the isoflavone daidzein, has been associated with beneficial health effects. Recent studies indicate that women with intestinal capacity to convert daidzein to equol also have the capacity to alter steroid metabolism and bioavailability of estrogens. METHODS: We evaluated whether individual equol production capability, while not consuming soy supplement, was associated with lower blood pressure in postmenopausal women using tibolone. In addition, in a randomized, placebo-controlled, cross-over trial we assessed the effect of soy supplementation on blood pressure in both equol-producing (n = 20) and non-equol-producing (n = 20) women using tibolone. Blood pressure was recorded with a validated oscillometric technique. RESULTS: The circulating equol levels rose 20-fold in the equol producers and 1.9-fold in the non-equol producers. At baseline, systolic blood pressure (129.9 +/- 2.6 vs. 138.5 +/- 3.1 mmHg, p = 0.02), diastolic blood pressure (72.2 +/- 1.5 vs. 76.6 +/- 1.3 mmHg, p = 0.01) and mean arterial blood pressure (93.5 +/- 1.7 vs. 99.9 +/- 1.8 mmHg, p = 0.007) were lower in equol producers compared to non-equol producers. Soy supplementation had no effect on blood pressure in either group, whereas the baseline differences persisted. CONCLUSIONS: Postmenopausal women using tibolone characterized as equol producers had lower blood pressure compared to non-equol producers. Soy supplementation for 2 months had no blood pressure-lowering effect.


Subject(s)
Blood Pressure/drug effects , Estrogen Receptor Modulators/administration & dosage , Isoflavones/biosynthesis , Norpregnenes/administration & dosage , Postmenopause/blood , Soybean Proteins/administration & dosage , Cross-Over Studies , Dietary Supplements , Double-Blind Method , Equol , Female , Genistein/metabolism , Humans , Male , Middle Aged , Phytoestrogens/metabolism , Postmenopause/drug effects , Treatment Outcome , Women's Health
10.
Gynecol Endocrinol ; 20(2): 116-20, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15823832

ABSTRACT

Results from the recent randomized clinical trials indicating that hormone therapy (HT) does not provide cardiovascular protection, but potential harm, are in profound disagreement with the sound evidence from numerous observational and experimental studies. While the observational studies have mainly assessed symptomatic recently menopausal women, the randomized trials have studied symptomless elderly postmenopausal women with established coronary heart disease or various risk factors for cardiovascular disease. Thus, the recent trials have revealed only that HT does not provide secondary cardiovascular benefits. Since primary cardiovascular benefits of HT are rational but not yet proven in clinical trials, new studies are in demand. Until more data from recently menopausal symptomatic women are available, we need to base our decisions on existing evidence and good clinical practice. Although the potential of HT to provide cardiovascular benefits is decreased by advancing age and time since menopause, this should not preclude the use of individualized HT in younger postmenopausal women.


Subject(s)
Cardiovascular Diseases/prevention & control , Estrogen Replacement Therapy , Menopause , Female , Humans , Middle Aged , Randomized Controlled Trials as Topic
SELECTION OF CITATIONS
SEARCH DETAIL
...